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window periods and false posi-
tive results. And clinics will need 
the ability to perform routine con-
firmatory testing, such as West-
ern blot analyses, among patients 
with positive results. These mea-
sures, along with detailed educa-
tional materials in package inserts, 
must be part of the home-market-
ing strategy.
Another controversial issue is 
cost. Currently, laboratories pay 
$12 to $17 for each OraQuick kit. 
The company expects to raise the 
price if over-the-counter status is 
approved, but it is not sure by how 
much. Public health officials argue 
that the test must be affordable to 
reach high-risk populations. A pilot 
study, sampling 240 HIV-positive 
patients, showed that most would 
pay no more than $15 for a 
test.4
Despite concern about afford-
ability and the potential for the 
misuse of results, there is still 
strong support for home HIV test-
ing. During the recent rash of false 
positive results, officials empha-
sized that the test remains an ex-
cellent screening tool, and many 
experts argue that the only way to 
halt the spread of the AIDS epi-
demic in the United States is to 
make HIV tests as simple as home 
pregnancy tests. If those who spoke 
at the FDA panel meeting in No-
vember are heard, the 20-year wait 
for a do-it-yourself HIV test may 
soon come to an end.
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in Developing Countries
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When the Group of Eight (G8) major industrial coun-
tries (France, the United States, 
Britain, Germany, Japan, Italy, 
Canada, and Russia) made a com-
mitment in July 2005 to work to-
ward universal access by 2010 to 
the prevention and treatment of 
human immunodeficiency virus 
(HIV) infection and AIDS, the 
move brought to light an HIV-
testing emergency: knowledge of 
serologic status is required for 
the appropriate targeting of ser-
vices and interventions. The World 
Health Organization and the Joint 
United Nations Program on HIV/
AIDS recently published revised 
guidelines for HIV testing,1 but 
field experience in Africa indi-
cates that testing must be greatly 
expanded. It seems clear that to 
maximize benefit, a public health 
approach to HIV testing and treat-
ment — including case finding 
and testing of partners — should 
become the norm.
Meeting the targets for anti-
retroviral treatment that had been 
set for the end of 2005 would 
have required testing as many as 
180 million persons worldwide 
annually,2 far exceeding the cur-
rent rates.3 Current guidelines rec-
ommend offering testing to per-
sons with symptoms and signs 
that are potentially attributable 
to HIV infection or AIDS.1 How-
ever, since advanced immunode-
ficiency can be clinically silent, it 
would be more effective to offer 
testing to all patients attending 
health care facilities in locations 
with a high prevalence of HIV in-
fection. Botswana, with a preva-
lence of more than 35 percent 
among people 15 to 49 years of 
age, has initiated such routine 
testing at clinics and hospitals 
nationwide. Kenya is increasing 
routine testing of pregnant wom-
en, hospitalized patients, and pa-
tients with tuberculosis; with an 
“opt-out” approach, less than 20 
percent have chosen not to be 
tested. With routine testing of 
inpatients in selected hospitals in 
Uganda, 95 percent of inpatients 
agreed to be tested, and the prev-
alence of HIV was discovered to 
exceed 50 percent.
Current guidelines restrict the 
use of routine testing to settings 
in which antiretroviral therapy is 
available.1 We believe that the 
recommendations should support 
routine testing wherever basic HIV 
care and prevention are available. 
Such a change would improve ef-
forts at prevention, allow infected 
persons to receive care such as 
cotrimoxazole prophylaxis, and 
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normalize HIV testing. Prophy-
laxis against opportunistic infec-
tions is within the reach of even 
the poorest countries, and the 
identification of those who will 
need it benefits the entire public 
health system. In the United 
States, it is cost-effective to pro-
vide routine testing and counsel-
ing to all patients in hospitals 
with a prevalence of HIV of more 
than 1 percent, a practice rec-
ommended by the Centers for 
Disease Control and Prevention 
(CDC); in Africa, the prevalence 
among hospitalized patients is 
often greater than 50 percent.
Providing testing to family 
members of infected persons is 
critical; 50 percent of the spous-
es of infected African adults are 
also infected.3 The testing of 
partners is the first step toward 
providing care for those who are 
infected — and protecting those 
who are not. Knowledge of HIV 
status is associated with reduc-
tions in high-risk behavior; and 
providing preventive services, in-
cluding condoms to HIV-discor-
dant couples, decreases the risk 
of transmission by 80 percent.4 
The children of infected women 
have an increased likelihood of 
infection, and pediatric HIV in-
fection may indicate the pres-
ence of infection in other family 
members. The identification and 
treatment to HIV-infected moth-
ers are important for their chil-
dren, since their risk of death is at 
least doubled if their mother dies.
The prevalence of HIV infec-
tion among adolescents, especial-
ly young women, is high in much 
of Africa. Counseling and testing 
among young people is an impor-
tant preventive strategy, al though 
it may be ethically and legally 
challenging. Although pre marital 
HIV testing is not cost-effective 
where prevalence is low, it is an 
important preventive practice in 
regions with generalized epidem-
ics. Careful guidance is required, 
however, to determine how to im-
plement such testing without co-
ercion and how to limit the neg-
ative social consequences of a 
premarital diagnosis of HIV infec-
tion, especially for young women.
Approximately 2.3 million chil-
dren worldwide are living with 
HIV infection, and children ac-
count for 18 percent of AIDS-
 related deaths. Signs of HIV dis-
ease are often nonspecific, and 
more than half of infected Afri-
can children die before two years 
of age. Antiretroviral therapy, 
therefore, must be started early, 
and universal HIV testing in pe-
diatric clinical settings — an is-
sue omitted from recent guide-
lines1 — will be required. 
Pediatric testing is complex: the 
possible presence of passively 
transferred maternal antibody lim-
its diagnostic confidence until 
18 months of age, and venipunc-
ture is difficult. Moreover, expo-
sure to HIV may continue during 
breast-feeding. Algorithms for 
testing children of various ages 
should be evaluated and endorsed 
by international public health 
authorities. For younger children, 
the algorithms could include rap-
id testing, with positive results 
verified by a central laboratory 
— a system being examined in 
Uganda and Kenya.
Since the denial of an HIV 
test may restrict an infected per-
son’s access to life-prolonging 
therapy, health care systems must 
determine whose role it is to 
grant permission for the testing 
of children, including orphans 
with no official guardians. In 
some countries, pediatric testing 
has been avoided for fear that 
HIV-infected children might be 
abandoned or neglected by fami-
lies or caregivers, but this has 
not, to our knowledge, been doc-
umented. Guidance is also re-
quired with regard to the appro-
priate timing and methods of 
disclosing to children their HIV 
status.
In Africa, AIDS-related mor-
tality is high among the provid-
ers of essential services — not 
only health care workers, but 
also teachers, police, and the 
military — so that stability, se-
curity, and economic development 
unfinished business — expanding hiv testing in developing countries
Traveling HIV Tester and Counselor in Kenya.
Service providers come by bicycle to remote areas with poor roads. In isolated desert 
regions, service delivery by camel is being developed.
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are all threatened. We recom-
mend routine testing for HIV for 
persons in key occupations, with 
guarantees of confidentiality, pro-
tection against discrimination, 
free treatment for infected per-
sons, and postexposure prophy-
laxis as appropriate.
The equitable expansion of 
HIV testing requires innovative 
approaches to reaching people in 
remote settings. New methods, 
such as finger-stick or salivary 
testing, are being used, and ser-
vices are being provided in in-
novative ways, including testing 
of entire families in health care 
facilities and homes. Testing and 
counseling services have been de-
livered at community and reli-
gious institutions, youth centers, 
and military barracks. The short-
age of health care professionals 
in Africa will have to be ad-
dressed in part by the training of 
community and lay workers to 
provide testing and counseling, 
treatment support, and other 
services.
Successful HIV-testing pro-
grams provide respectful and 
convenient service, confidential-
ity, accurate testing, full infor-
mation, and effective referral. 
Rapid test algorithms involving 
the use of different tests in com-
bination have a validity similar 
to that of standard approaches,5 
do not require laboratory facili-
ties or confirmation by Western 
blot assay, and can be performed 
by trained lay personnel. Per-
forming rapid tests on finger-
stick specimens in front of clients 
increases confidence in the re-
sults and prevents clerical errors. 
Tests may be performed sequen-
tially or in parallel, with a third 
test used as a “tie breaker” for 
discrepant results. A subgroup 
of specimens may be sent to a 
laboratory for quality assurance.
Vigorous treatment and pre-
vention programs limit the dev-
astation wrought by AIDS, moti-
vating a reassessment of attitudes 
toward HIV testing. The initial 
experience in Africa shows that 
the benefits outweigh the risks. 
According to Rose Apondi, a re-
searcher at CDC–Uganda who 
studied HIV-infected persons in 
rural Uganda, home-based HIV 
testing and three months of an-
tiretroviral therapy were associ-
ated with exclusively positive 
social experiences, such as com-
munity and partner support, in 
79 percent of cases and with ex-
clusively negative ones, such as 
stigma, in less than 1 percent.
HIV epidemics have also 
emerged in countries such as 
China, India, and Russia, where 
they are concentrated among in-
jection-drug users, sex workers 
and their clients, and paid blood 
donors. Ensuring the appropri-
ate distribution of services will 
require sentinel surveillance, fol-
lowed by HIV testing targeted 
according to local epidemiologic 
trends. These countries have an 
opportunity that was not afford-
ed to countries in Africa: before 
their epidemics become general-
ized, they may develop integrated 
strategies linking surveillance, 
prevention, HIV testing, antiretro-
viral therapy, and other care.
The increased resources avail-
able for combating HIV and 
AIDS, the strong emphasis on 
treatment, and the commitment 
of the G8 to universal access ne-
cessitate a massive expansion of 
HIV testing. The ideal that all 
citizens of high-prevalence coun-
tries should know their serologic 
status and should be tested re-
peatedly over the course of their 
lives should become explicit tar-
gets of preventive efforts. In-
creased rates of testing will, of 
course, generate other challeng-
es, such as the provision of pre-
ventive services for HIV-infected 
persons, the disclosure of sero-
logic status, and the notification 
of partners — all areas in which 
we must define the best practic-
es for a new era.
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